Carlos Orrego, MD
Cardiovascular Disease · Phoenix, AZNPI 1568599876
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $8,130 of the $9,426 with a category attached, or 86.2%. 31 manufacturers reported payments, led by Boston Scientific at 33.0% of the total. Reporting peaked in 2024 at $3,127 and has fallen 57.2% since, to $1,339 in 2025.
Across 208 payments — averaging $45.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$3K
- Actelion Pharmaceuticals US, Inc.$830
- Merck$769
- AstraZeneca$569
- Novo Nordisk$531
- Abbott$454
- plus $3K from 25 others
Across 2 payments — averaging $27,031 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$54K
What the payments were for
- Travel & lodging$1,18613%
- Food & beverage$8,13086%
- Education$1111%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 37 | $3,115 |
| Actelion Pharmaceuticals US, Inc. | 20 | $830 |
| Merck | 30 | $769 |
| AstraZeneca | 22 | $569 |
| Novo Nordisk | 7 | $531 |
| Abbott | 9 | $454 |
| E.r. Squibb & Sons, L.L.C. | 12 | $402 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 14 | $402 |
| Impulse Dynamics (USA) Inc. | 5 | $310 |
| Boehringer Ingelheim | 5 | $207 |
| Inspire Medical Systems, Inc. | 3 | $164 |
| Cleerly, Inc. | 3 | $149 |
| Bardy Diagnostics, Inc. | 8 | $140 |
| Medtronic | 1 | $138 |
| Pfizer | 2 | $132 |
| Amarin Pharma, Inc. | 3 | $131 |
| Madrigal Pharmaceuticals | 1 | $126 |
| Eisai Inc. | 1 | $117 |
| Phathom Pharmaceuticals, Inc. | 1 | $107 |
| Johnson & Johnson | 6 | $105 |
| Therapeuticsmd, Inc. | 1 | $105 |
| RARE Disease Therapeutics, Inc. | 1 | $97 |
| Bridgebio Pharma, Inc. | 3 | $86 |
| Novartis | 4 | $85 |
| Amgen | 3 | $61 |
| Alnylam Pharmaceuticals Inc. | 1 | $19 |
| Astellas Pharma US Inc | 1 | $18 |
| Edwards Lifesciences | 1 | $16 |
| Bayer | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
| Acarix USA Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VERQUVO$527
- OPTIMIZER$318
- UPTRAVI$263
- OPSUMIT$263
- WATCHMAN FLX$172
- Proclaim IPG$152
- INTELLIS ADAPTIVESTIM$138
- REZDIFFRA$126
- LifeVest$124
- EMBLEM$124
- Merlin Connectivity and Remote$123
- JARDIANCE$121
- Vascepa$119
- Inspire$118
- Leqembi$117
- CAMZYOS$116
- LUX-Dx Insertable Cardiac Monitor$116
- Enhertu$115
- VYNDAQEL$115
- Watchman$111
How this compares
$9,426 in reported general payments places this provider in the 75th percentile of 423 cardiovascular disease providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 47 | $68,193 |
| XareltoRivaroxaban | 34 | $34,561 |
| EntrestoSacubitril/Valsartan | 22 | $23,069 |
| FarxigaDapagliflozin Propanediol | 13 | $20,794 |
| Ezetimibe | 12 | $894 |
| Atorvastatin Calcium | 78 | $888 |
| Metoprolol Succinate | 56 | $672 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 25 | $670 |
| Carvedilol | 60 | $552 |
| Losartan Potassium | 55 | $468 |
| Amlodipine Besylate | 41 | $452 |
| Furosemide | 48 | $310 |
| Lisinopril | 39 | $261 |
| Spironolactone | 30 | $248 |
| ClopidogrelClopidogrel Bisulfate | 33 | $227 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $132 | $68,19347 claims |
| Johnson & JohnsonXarelto | $105 | $34,56134 claims |
| NovartisEntresto | $85 | $23,06922 claims |
| AstraZenecaFarxiga | $569 | $20,79413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 423 cardiovascular disease providers in Arizona.
Other cardiovascular disease in Phoenix
- Ashish GuptaPhoenix$1.1M
- Rajkumar SugumaranPhoenix$957K
- Tabitha MoePhoenix$182K
- Jesse SethiPhoenix$150K
- Robert ScottPhoenix$106K
- Kethes WaramPhoenix$66K
- Ayman JamalPhoenix$42K
- Sarika DesaiPhoenix$41K
- Suzanne SorofPhoenix$29K
- Namit RohantPhoenix$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.